Eide, Peter W.
Moosavi, Seyed H.
Eilertsen, Ina A.
Brunsell, Tuva H.
Langerud, Jonas
Berg, Kaja C. G.
Røsok, Bård I.
Bjørnbeth, Bjørn A.
Nesbakken, Arild
Lothe, Ragnhild A. http://orcid.org/0000-0002-1693-1032
Sveen, Anita http://orcid.org/0000-0001-8219-6251
Article History
Received: 15 January 2021
Accepted: 22 June 2021
First Online: 14 July 2021
Competing interests
: P.W.E., A.N., R.A.L., and A.S. are co-inventors of a pending patent application (Attorney Docket Number: INVEN-35063/US-1/PRO) regarding the use of HSP90 inhibitors in relation to the consensus molecular subtypes of colorectal cancer. A disclosure of invention of a de novo liver metastasis transcriptomic subtyping framework (S.H.M., R.A.L., and A.S.; not referred to in this manuscript) has been reported to Inven2, a technology transfer office and limited liability company owned by Oslo University Hospital and the University of Oslo. The authors have no other competing interests.